dc.creator | Olmedo Martín, Raúl Vicente | es |
dc.creator | Vázquez Morón, Juan María | es |
dc.creator | Martín Rodríguez, María del Mar | es |
dc.creator | Lázaro Sáez, Marta | es |
dc.creator | Hernández Martínez, Álvaro | es |
dc.creator | Argüelles Arias, Federico | es |
dc.date.accessioned | 2024-05-09T13:19:25Z | |
dc.date.available | 2024-05-09T13:19:25Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Olmedo Martín, R.V., Vázquez Morón, J.M., Martín Rodríguez, M.d.M., Lázaro Sáez, M., Hernández Martínez, Á. y Argüelles Arias, F. (2023). Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study. Revista Española de Enfermedades Digestivas, 115 (12), 686-692. https://doi.org/10.17235/reed.2023.9402/2022. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158006 | |
dc.description.abstract | Background: ustekinumab has proven effective in Crohn’s
disease (CD). However, some patients will partially respond
or lose response over time. Data supporting the effective ness of dose escalation in this scenario is scarce.
Aim: to evaluate the effectiveness of ustekinumab dose es calation in CD.
Methods: patients with active CD (Harvey-Bradshaw ≥ 5)
who had received intravenous (IV) induction and at least a
subcutaneous (SC) dose were included in this retrospective
observational study. Ustekinumab dose was escalated, ei ther via shortening of the interval to six or four weeks or IV
reinduction plus shortening to every four weeks.
Results: ninety-one patients were included, and ustekinum ab dose was escalated after a median of 35 weeks of treat ment. At week 16 after intensification, steroid-free clinical
response and remission were observed in 62.6 % and
25.3 % of patients, respectively. Systemic corticosteroids
were discontinued in 46.7 % of patients who were on cor ticosteroids at baseline. Follow-up data beyond week 16
were available for 78 % of patients; at the last visit, 66.2 %
and 43.7 % were in steroid-free clinical response and remis sion, respectively. After a median follow-up of 64 weeks,
81 % of patients were still treated with ustekinumab. Ad verse events were reported in 4.3 % of patients; these were
all mild and did not lead to hospitalization or discontinua tion of treatment. Five patients (5.5 %) underwent surgical
resection, with no immediate postsurgical complications.
Conclusion: ustekinumab dose escalation was effective in
recapturing response in over half of the patients. These
findings suggest that dose escalation should be considered
in patients who experience loss or partial response to the
standard maintenance. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 115 (12), 686-692. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Ustekinumab | es |
dc.subject | Crohn’s disease | es |
dc.subject | Dose escalation | es |
dc.subject | Reinduction | es |
dc.title | Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=12669&hst=0&idR=127&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2023.9402/2022 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 115 | es |
dc.publication.issue | 12 | es |
dc.publication.initialPage | 686 | es |
dc.publication.endPage | 692 | es |